Parkside Financial Bank & Trust’s Arcutis Biotherapeutics ARQT Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12K	Hold	119	–	–	﹤0.01%	2039
2026 Q1	$2.8K	Hold	119	–	–	﹤0.01%	2002
2025 Q4	$3.46K	Hold	119	–	–	﹤0.01%	1916
2025 Q3	$2.24K	Hold	119	–	–	﹤0.01%	1981
2025 Q2	$1.67K	Buy	119 +39	+49%	+$547	﹤0.01%	2062
2025 Q1	$1.25K	Buy	+80	New	+$1.13K	﹤0.01%	2034

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parkside Financial Bank & Trust's ARQT Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 119 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2039.

Parkside Financial Bank & Trust first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.46K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Parkside Financial Bank & Trust held 119 shares of Arcutis Biotherapeutics worth $3.12K as of Q2 2026.
Parkside Financial Bank & Trust left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2039 holding.
Parkside Financial Bank & Trust first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
Parkside Financial Bank & Trust's Arcutis Biotherapeutics position peaked at $3.46K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.